<unk>  is indicated treating chronic hepatic C (CHC) infection as a part of a triple antiviral treatment regimen consisting of two other drugs: peginterferon-alfa (PEG-IFN) and ribavirin (RBV). It is primarily effective in treating Hepatitis C virus (HCV) genotype 1 infected subjects with compensated liver disease, including cirrhosis. There are currently no studies that show<unk> 's effectiveness as a single therapy for HCV.<unk>  is generally used for HCV genotype 1 infected subjects, but off-label medical use has been indicated for type 4 genotype as well. Dosing<unk>  is dosed along with peg-IFN and RBV as triple therapy. Appropriate dosing of<unk>  is dependent upon the patient's liver function, kidney function, viral load, and HCV genotype. This medication is not recommended for people with moderate or severe liver impairment and people with end-stage kidney disease since<unk>  was not studied for use in these patient populations.<unk>  might be discontinued depending on their viral load. For instance, if the patient's viral load is detectable (>25 units/mL) during the 4th week of their treatment regimen, it is considered an inadequate treatment and<unk>  must be discontinued.
Simeprevir
Saquinavir
Telaprevir
Fosamprenavir
Glecaprevir
Abacavir
Indinavir
Fostemsavir